Alterity Therapeutics Limited American Depositary Shares

The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical tr...

The rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as ...

MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will presen...

- New bioMUSE Data Informs ATH434-202 Study Endpoints -

- ATH434-201 Trial on Track to Complete in November 2024 –